Send to

Choose Destination
Transpl Immunol. 2013 Dec;29(1-4):7-10. doi: 10.1016/j.trim.2013.08.003. Epub 2013 Aug 29.

Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: a single-center experience.

Author information

Renal Transplantation, Hospital Alemán, Pueyrredón 1640, C1118AAT Buenos Aires, Argentina; Foundation for Research and Assistance in Renal Disease (FINAER), 503 No. 1947, B1897FYU Gonnet, La Plata, Buenos Aires, Argentina. Electronic address:


Donor-specific human leukocyte antigen (HLA) antibodies (DSA) are associated with decreased graft survival and may cause graft rejection. Bortezomib, a selective inhibitor of the 26S proteasome developed to treat multiple myeloma, has been used for its anti-plasma cell activity in patients undergoing transplantation. We describe our experience with bortezomib used to reduce anti-HLA antibodies in eight renal transplant patients. Patients received bortezomib (1.3mg/m(2)) on days 1, 4, 8, and 11 beginning when antibodies were detected. It was used alone in one patient and was complemented with plasmapheresis in five patients, with IVIG in one patient, and with IVIG and plasmapheresis in another patient. De novo DSA class II were detected in all eight patients and two also had DSA class I. Antibodies were entirely eliminated in five (62.5%) patients 90 days after treatment but only reduced in the other three (62.5%). Notably, they later increased in one patient. Five (62.5%) patients had AMR, two (25%) had mixed rejection, and one had no rejection. our results suggest that bortezomib is effective for reducing DSA avoiding chronic graft injury.


Alloantibody; Bortezomib; HLA; Kidney; Proteasome inhibitor; Transplantation

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center